Lithium Ion

Lithium Ion

SCHEMBL912832

Fc1ccccc1[B-](c1ccccc1F)(c1ccccc1F)c1ccccc1F.[Li+]

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.39
NFE2L2 Q16236 4/20 0.38
CES2 O00748 2/20 0.35
CES1 P23141 2/20 0.35
TAAR1 Q96RJ0 1/20 0.33
ALDH1A1 P00352 2/20 0.32
ALOX15 P16050 1/20 0.32
IDO1 P14902 2/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
KDM1A O60341 1/20 0.30
KDM1B Q8NB78 1/20 0.30
MGLL Q99685 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
DCTPP1 Q9H773 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL29567735 1.00 ACHE (0.39) ACHENFE2L2CES2CES1TAAR1
SCHEMBL123954 0.97 ACHE (0.41) ACHENFE2L2CES2CES1TAAR1
SCHEMBL1450796 0.94 ACHE (0.39) ACHENFE2L2CES2CES1TAAR1
SCHEMBL29830966 0.94 ACHE (0.39) ACHENFE2L2CES2CES1TAAR1
SCHEMBL1452107 0.94 ACHE (0.39) ACHENFE2L2CES2CES1TAAR1
Silver SCHEMBL1450856 0.94 ACHE (0.39) ACHENFE2L2CES2CES1TAAR1
Bromide SCHEMBL7211405 0.92 ACHE (0.38) ACHENFE2L2CES2CES1TAAR1
Bromide SCHEMBL7211403 0.92 ACHE (0.38) ACHENFE2L2CES2CES1TAAR1
Lithium Ion SCHEMBL1493096 0.82 CES2 (0.40) ACHENFE2L2CES2CES1TAAR1
SCHEMBL20841980 0.81 ACHE (0.35) ACHENFE2L2CES2CES1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638569-A1 SUPPORTED MEMBRANES BY THERMAL AND UV INITIATED MASS POLYMERIZATION Promerus, LLC (US) 2025-10-29 EP claimed
EP-4584309-A1 POLYCYCLIC-OLEFINIC POLYMERS CONTAINING ACRYLATE FUNCTIONALITY WITH ACRYLATE/MALEIMIDE CROSSLINKERS AS B-STAGEABLE COMPOSITIONS FOR LOW LOSS APPLICATIONS Promerus, LLC (US) 2025-07-16 EP claimed
US-12251668-B2 Supported membranes by thermal and UV initiated mass polymerization PROMERUS, LLC (US) 2025-03-18 US claimed
EP-4504803-A1 PALLADIUM CATALYSTS FOR FORMING VINYL ADDITION POLYMERS HAVING IMPROVED FILM FORMING PROPERTIES Promerus, LLC (US) 2025-02-12 EP claimed
US-20240216875-A1 SUPPORTED MEMBRANES BY THERMAL AND UV INITITATED MASS POLYMERIZATION PROMERUS, LLC (US) 2024-07-04 US claimed
WO-2024137739-A1 SUPPORTED MEMBRANES BY THERMAL AND UV INITIATED MASS POLYMERIZATION PROMERUS, LLC (US) 2024-06-27 WO claimed
US-20240141087-A1 POLYCYCLIC-OLEFINIC POLYMERS CONTAINING ACRYLATE FUNCTIONALITY WITH ACRYLATE/MALEIMIDE CROSSLINKERS AS B-STAGEABLE COMPOSITIONS FOR LOW LOSS APPLICATIONS PROMERUS, LLC (US) 2024-05-02 US claimed
WO-2024054548-A1 POLYCYCLIC-OLEFINIC POLYMERS CONTAINING ACRYLATE FUNCTIONALITY WITH ACRYLATE/MALEIMIDE CROSSLINKERS AS B-STAGEABLE COMPOSITIONS FOR LOW LOSS APPLICATIONS PROMERUS, LLC (US) 2024-03-14 WO claimed
US-11845880-B2 Polycyclic-olefinic compositions for low-loss films having improved thermal properties PROMERUS, LLC (US) 2023-12-19 US claimed
WO-2023196366-A1 PALLADIUM CATALYSTS FOR FORMING VINYL ADDITION POLYMERS HAVING IMPROVED FILM FORMING PROPERTIES PROMERUS, LLC (US) 2023-10-12 WO claimed
US-20170058145-A1 POLYCYCLOOLEFIN POLYMER COMPOSITIONS AS OPTICAL MATERIALS PROMERUS, LLC (US) 2017-03-02 US claimed
US-20160289353-A1 CHAIN TRANSFER AGENT FOR ADDITION MASS POLYMERIZATION OF POLYCYCLOOLEFINIC MONOMERS SUMITOMO BAKELITE CO., LTD. (JP) 2016-10-06 US claimed
US-9415354-B2 Organopalladium compounds as polymerization catalysts PROMERUS, LLC (US) 2016-08-16 US claimed
US-20160046657-A1 ORGANOPALLADIUM COMPOUNDS AS POLYMERIZATION CATALYSTS SUMITOMO BAKELITE CO., LTD. (JP) 2016-02-18 US claimed
EP-1034196-B1 CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS PROMERUS LLC (US) 2005-01-12 EP claimed
US-20030023013-A1 Catalyst and methods for polymerizing cycloolefins THE B.F.GOODRICH COMPANY 2003-01-30 US claimed
US-6455650-B1 CONTACTING POLYCYCLOOLEFIN MONOMER WITH A HIGH ACTIVITY GROUP 10 TRANSITION METAL CATALYST COMPLEX TO OBTAIN POLYMER PRODUCT THE B.F. GOODRICH COMPANY 2002-09-24 US claimed
US-20020052454-A1 CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS SUMITOMO BAKELITE CO., LTD. (JP) 2002-05-02 US claimed
EP-1034196-A1 CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS THE B.F. GOODRICH COMPANY (US) 2000-09-13 EP claimed
WO-2000020472-A1 CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS THE B.F. GOODRICH COMPANY (US) 2000-04-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046657-A1 ORGANOPALLADIUM COMPOUNDS AS POLYMERIZATION CATALYSTS MVD, DDT, CDV3 ACHE 430/4885NFE2L2 596/4885CES2 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.